KR20180004104A - 코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법 - Google Patents

코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법 Download PDF

Info

Publication number
KR20180004104A
KR20180004104A KR1020177026735A KR20177026735A KR20180004104A KR 20180004104 A KR20180004104 A KR 20180004104A KR 1020177026735 A KR1020177026735 A KR 1020177026735A KR 20177026735 A KR20177026735 A KR 20177026735A KR 20180004104 A KR20180004104 A KR 20180004104A
Authority
KR
South Korea
Prior art keywords
pharmacologically active
active agent
cochleate
tissue
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177026735A
Other languages
English (en)
Korean (ko)
Inventor
라파엘 제이. 만니노
루잉 루
Original Assignee
마티나스 바이오파마 나노테크놀로지스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 filed Critical 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드
Publication of KR20180004104A publication Critical patent/KR20180004104A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
KR1020177026735A 2015-03-03 2016-03-03 코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법 Ceased KR20180004104A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562127799P 2015-03-03 2015-03-03
US62/127,799 2015-03-03
US201562162425P 2015-05-15 2015-05-15
US62/162,425 2015-05-15
US201562163212P 2015-05-18 2015-05-18
US62/163,212 2015-05-18
US201562239675P 2015-10-09 2015-10-09
US62/239,675 2015-10-09
US201562247641P 2015-10-28 2015-10-28
US62/247,641 2015-10-28
US201562264164P 2015-12-07 2015-12-07
US62/264,164 2015-12-07
PCT/US2016/020722 WO2016141203A1 (en) 2015-03-03 2016-03-03 Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent

Publications (1)

Publication Number Publication Date
KR20180004104A true KR20180004104A (ko) 2018-01-10

Family

ID=56848705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026735A Ceased KR20180004104A (ko) 2015-03-03 2016-03-03 코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법

Country Status (8)

Country Link
US (1) US11389407B2 (enExample)
EP (1) EP3265060B1 (enExample)
JP (1) JP6770524B2 (enExample)
KR (1) KR20180004104A (enExample)
CN (1) CN107847443A (enExample)
AU (1) AU2016226151B2 (enExample)
CA (1) CA2978308C (enExample)
WO (1) WO2016141203A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018337955B2 (en) * 2017-09-20 2024-01-18 Atopic Medical, Inc. Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa
CN107621514B (zh) * 2017-11-10 2020-09-29 成都美域高制药有限公司 高效液相色谱法测定磷酸特地唑胺对映异构体含量的方法
KR101989789B1 (ko) * 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
WO2019199238A1 (en) * 2018-04-09 2019-10-17 Vet Products Research And Innovation Center Company Limited Inorganic mineral entrapped in nanoparticle production method thereof
JP2022544077A (ja) * 2019-08-13 2022-10-17 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド クリプトコッカス感染症を治療する方法
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5643574A (en) 1993-10-04 1997-07-01 Albany Medical College Protein- or peptide-cochleate vaccines and methods of immunizing using the same
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
AU2003254598A1 (en) 2002-08-06 2004-02-23 Tuo Jin Cochleates without metal cations as the bridging agents
WO2004064805A1 (en) * 2003-01-15 2004-08-05 Biodelivery Sciences International, Inc. Cochleate preparations of fragile nutrients
US20050013854A1 (en) 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
JP4789208B2 (ja) 2003-04-09 2011-10-12 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド タンパク質発現に向けられた渦巻型組成物
WO2005110361A2 (en) * 2004-04-09 2005-11-24 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
SG190613A1 (en) * 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
JP6347743B2 (ja) * 2011-05-05 2018-06-27 マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド コクリエート組成物およびその製造および使用方法
WO2013085152A1 (en) * 2011-12-07 2013-06-13 Union Korea Pharm Co., Ltd. Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors
MX361155B (es) 2012-07-30 2018-11-28 Matinas Biopharma Nanotechnologies Inc Cocleatos hechos con fosfatidilserina de soja.
CN108136212A (zh) 2015-04-22 2018-06-08 马丁尼斯生物制药纳米技术公司 用于治疗分枝杆菌感染和肺病的组合物和方法
CN107920991A (zh) 2015-06-18 2018-04-17 马丁尼斯生物制药纳米技术公司 治疗炎性疾病或病状的组合物和方法

Also Published As

Publication number Publication date
EP3265060A4 (en) 2018-08-22
WO2016141203A1 (en) 2016-09-09
CA2978308C (en) 2024-02-13
JP6770524B2 (ja) 2020-10-14
US20180042849A1 (en) 2018-02-15
EP3265060B1 (en) 2020-10-21
JP2018508523A (ja) 2018-03-29
US11389407B2 (en) 2022-07-19
AU2016226151A1 (en) 2017-09-21
CA2978308A1 (en) 2016-09-09
CN107847443A (zh) 2018-03-27
EP3265060A1 (en) 2018-01-10
AU2016226151B2 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
KR20180004104A (ko) 코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법
JP6923206B2 (ja) マイコバクテリア感染症及び肺疾患を治療するための組成物及び方法
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
CN107261110A (zh) Peg化脂质体包封的糖肽抗生素的新制剂
JP2023518694A (ja) 感染性疾患又は呼吸器疾患の予防的処置又は曝露後処置に使用するための抗ウイルス剤の組成物
Palazzo et al. Development of injectable liposomes and drug-in-cyclodextrin-in-liposome formulations encapsulating estetrol to prevent cerebral ischemia of premature babies
US11318097B1 (en) ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US20250064784A1 (en) Liposome composition comprising liposomal prodrug of mitomycin c and methods of treatment
JP2025026896A (ja) リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用
US20230129331A1 (en) Liposomal formulations comprising at1 receptor blockers and uses thereof
US20180185308A1 (en) Compositions and methods for treating inflammatory disease or conditions
EP4529915A1 (en) Liposomal preparations for use in treating cancer
Estanqueiro et al. Lipid-based nanocarriers in cancer therapy
HK40082187A (en) Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases
OA20783A (en) Carotenoid compositions and uses thereof
HK40035547B (zh) 用於治疗剂的肠胃外施用的组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170921

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210218

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230226

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230829

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230226

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230829

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230417

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210218

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240130

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231130

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230829

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230417

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230226

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210218

X601 Decision of rejection after re-examination